Article ; Online: New-Onset MDA-5 Dermatomyositis in a Patient Following COVID-19 Vaccination: A Case Report.
Mediterranean journal of rheumatology
2024 Volume 35, Issue 1, Page(s) 179–183
Abstract: Vaccination against Sars-CoV-2 has been proven to significantly reduce COVID-19 morbidity and mortality and is therefore recommended for the general population, and especially for seniors with impaired immunity. However, it is currently postulated that ... ...
Abstract | Vaccination against Sars-CoV-2 has been proven to significantly reduce COVID-19 morbidity and mortality and is therefore recommended for the general population, and especially for seniors with impaired immunity. However, it is currently postulated that COVID-19 vaccines could rarely induce autoimmune diseases in previously healthy individuals. We report a case of new-onset anti-melanoma differentiation-associated protein 5 (anti-MDA5) antibody-positive dermatomyositis in a patient presenting with rash and fever following the third dose of COVID-19 vaccine. The laboratory testing revealed high titres of anti-MDA-5 antibody and chest computed tomography showed micronodular lesions and ground glass opacities bilaterally. The patient was promptly treated with corticosteroids, methotrexate, and azathioprine, and was later started on rituximab due to dermatomyositis rash exacerbation along with newly formed, diffuse skin ulcers. Our case highlights the potential immunogenicity of COVID-19 vaccines and the need for further reporting of rare rheumatic syndromes possibly related to COVID-19 disease and vaccination. |
---|---|
Language | English |
Publishing date | 2024-03-31 |
Publishing country | Greece |
Document type | Case Reports |
ZDB-ID | 3019943-8 |
ISSN | 2529-198X ; 2459-3516 |
ISSN (online) | 2529-198X |
ISSN | 2459-3516 |
DOI | 10.31138/mjr.280124.nom |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.